Is a Generic Ozempic Available Yet?
No generic version of Ozempic (semaglutide injection) exists as of 2024. The brand is made by Novo Nordisk and remains under patent protection, blocking FDA approval of generics until key patents expire.[1]
When Do Ozempic Patents Expire?
Core composition-of-matter patents for semaglutide run until at least 2031 in the US, with some formulation and device patents extending to 2032. Novo Nordisk lists 19 Orange Book patents, the latest expiring December 2032. No generic entry is expected before 2032 without successful challenges.[2][3]
Why Is Generic Ozempic Delayed?
Novo Nordisk faces over 20 ANDA filings from generic makers like Hims & Hers, but all are stalled by patent litigation. A federal court upheld the patents in 2024, dismissing Teva's challenge. Appeals could drag on for years.[2]
What About Compounded Semaglutide?
Compounded versions from pharmacies mimic Ozempic but aren't FDA-approved generics. The FDA ended the semaglutide shortage in 2024, declaring most compounded copies adulterated and illegal to sell. Patients risk safety issues like dosing errors or contamination.[1][4]
When Could Biosimilars Arrive?
Ozempic is a biologic, so interchangeable biosimilars—not traditional generics—are the path forward. No approvals yet; earliest entry likely post-2031 patents, similar to Humira biosimilars after 2023 patent cliffs. Mylan (Viatris) and others have filed, but litigation blocks progress.[2][5]
Cheaper Alternatives Right Now
Wegovy (higher-dose semaglutide from Novo Nordisk) has similar patents but no generics either. GLP-1 rivals like Zepbound (tirzepatide, Eli Lilly) or discounted Rybelsus (oral semaglutide) offer options. Generic liraglutide (Victoza/Saxenda) launched in 2023 as a lower-cost GLP-1 alternative.[3][6]
[1]: FDA.gov - Ozempic Shortage Update
[2]: DrugPatentWatch.com - Ozempic Patents
[3]: FDA Orange Book - Ozempic Entry
[4]: FDA.gov - Compounded Semaglutide Risks
[5]: FDA.gov - Biosimilar Approvals
[6]: GoodRx - GLP-1 Alternatives